Frontiers in Cardiovascular Medicine最新文献

{"title":"One-year unplanned readmission after percutaneous coronary intervention in ST-elevation myocardial infarction: rates, causes, and predictors-a retrospective cohort study.","authors":"O Alkhalaila, A Rahhal, M Altermanini, M S Abdelghani, M Shehadeh, K Shunnar, M B Habib, Y Hailan, M Barakat, M H Alkhateeb, M Al-Hijji, A R Arabi","doi":"10.3389/fcvm.2025.1581371","DOIUrl":"10.3389/fcvm.2025.1581371","url":null,"abstract":"<p><strong>Background: </strong>Unplanned readmissions after percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) significantly impact healthcare systems. However, most of the existing literature focuses on short-term readmission rates and causes, with limited data on long-term readmissions. To date, no studies have evaluated the unplanned readmission post-PCI in STEMI patients within the Arab Gulf region. This study aimed to determine the rates, causes, and predictors of readmission post-PCI among STEMI patients over a one-year follow-up in Qatar, one of the Arab Gulf countries.</p><p><strong>Methods: </strong>We conducted a single-center retrospective cohort study at Hamad Medical Corporation in Qatar, involving 1,257 patients who underwent PCI during their index STEMI admission between January 1, 2016, and September 30, 2018. Patients were divided into two groups; (1) those who had one or more unplanned readmission within one year after PCI; (2) and those who did not have readmissions. The outcomes evaluated were the rates, causes, and predictors of all-cause and cardiac readmissions within one year post-PCI.</p><p><strong>Results: </strong>The mean age of the study population was 51 ± 10 years, and male gender presented 96%. The rate of all-cause readmission within one year post-PCI was 11.5%, with 8.2% due to cardiac reasons. Positive predictors of all-cause readmission included female gender (aOR = 4.14, 95% CI 2.10-8.18, <i>p</i> < 0.001), chronic kidney disease (aOR = 2.76, 95% CI 1.07-7.08, <i>p</i> = 0.035), more than one stent during PCI (aOR = 1.66, 95% CI 1.09-2.55, <i>p</i> = 0.019), and clinical heart failure during the index admission (aOR = 2.36, 95% CI 1.49-3.74, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>This study highlights the need for targeted management strategies for high-risk populations to reduce readmission rates.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1581371"},"PeriodicalIF":2.8,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of estimated pulse wave velocity with cardiovascular disease outcomes and all-cause death-a systematic review and meta-analysis.","authors":"Jian Li, Fa Gao, Fang Cao, Shan Lv, Yulong Hou, Wei Guo, Chongheng Zhang, Aidong Liu","doi":"10.3389/fcvm.2025.1641697","DOIUrl":"10.3389/fcvm.2025.1641697","url":null,"abstract":"<p><strong>Background: </strong><b>:</b> The estimated pulse wave velocity (ePWV), derived from age and mean blood pressure (MBP) in accordance with the Reference Values of Arterial Stiffness Collaboration, has emerged as a novel alternative indicator for assessing arterial stiffness. This systematic review and meta-analysis aims to assess the correlation of ePWV with the likelihood of adverse cardiovascular (CV) events and all-cause mortality.</p><p><strong>Methods: </strong>Studies published before February 2024 from PubMed, Embase, Cochrane Library, and Web of Science were searched. To ensure the completeness and timeliness of the included literature, a thorough re-search and update of the relevant literature were conducted on April 28, 2025. The data analysis was carried out utilizing STATA (V15.0).</p><p><strong>Results: </strong>A systematic review and meta-analysis of 20 studies involving 381,303 participants demonstrated that individuals with higher ePWV had significantly increased risks of total CV events (HR = 2.14, 95%CI: 1.70-2.71), CV mortality (HR = 3.64, 95%CI: 2.83-4.68), and all-cause mortality (HR = 1.85, 95%CI: 1.38-2.47). Specifically, for each 1 m/s increase in ePWV, the risks of these outcomes increased by 36%, 41%, and 37%, respectively. Analyses of population types further verified that elevated ePWV was independently associated with increased risks for all outcomes. For total CV events, the HRs were 1.79 (95%CI: 1.45-2.21) in the general population and 3.43 (95%CI: 2.62-4.49) in those with CVD. For CV mortality, the HRs were 4.90 (95%CI: 2.78-8.64) and 3.39 (95%CI: 2.56-4.49), respectively. For all-cause mortality, HRs were 2.28 (95%CI: 1.00-5.21) in the general population and 1.84 (95%CI: 1.20-1.42) in the CVD group. Moreover, each 1 m/s increase in ePWV was associated with a 27% and 54% increase in total CV event risk, a 28% and 54% increase in CV mortality, and a 47% and 30% increase in all-cause mortality in the general and CV populations, respectively.</p><p><strong>Conclusion: </strong>These findings highlight ePWV as a potential predictor of adverse health outcomes, warranting further research to establish reference values and compare with carotid-femoral pulse wave velocity.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42024536235.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1641697"},"PeriodicalIF":2.8,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing changes in abdominal aortic aneurysms using principal wall strain ultrasound elastography.","authors":"Baqir J Kedwai, Zachary R Zottola, Daniel J Lehane, Joshua T Geiger, Micheal C Stoner, Michael S Richards, Doran S Mix","doi":"10.3389/fcvm.2025.1613881","DOIUrl":"10.3389/fcvm.2025.1613881","url":null,"abstract":"<p><strong>Introduction: </strong>Aortic principal wall strain is a biomechanical parameter correlated with aneurysm growth rate that affects abdominal aortic aneurysm (AAA) stability. Characterize changes in pressure-normalized maximum mean aortic principal wall strain <math><mo>(</mo> <mrow> <mover><msub><mi>ε</mi> <mrow><mi>ρ</mi> <mo>+</mo></mrow> </msub> <mo>¯</mo></mover> <mrow><mo>/</mo> <mi>PP</mi></mrow> </mrow> <mo>)</mo></math> using ultrasound elastography (USE).</p><p><strong>Methods: </strong>Axial ultrasound images of patient AAAs were collected at two consecutive clinic visits. The <math> <mover><msub><mi>ε</mi> <mrow><mi>ρ</mi> <mo>+</mo></mrow> </msub> <mo>¯</mo></mover> <mrow><mo>/</mo> <mi>PP</mi></mrow> </math> for each image was calculated using a novel finite element mesh technique. The cohort was separated by index <math> <mover><msub><mi>ε</mi> <mrow><mi>ρ</mi> <mo>+</mo></mrow> </msub> <mo>¯</mo></mover> <mrow><mo>/</mo> <mi>PP</mi></mrow> </math> terciles, and the rate of strain change, growth, intervention, and rupture were compared.</p><p><strong>Results: </strong>31 patients with a median age of 72.0 [65.0, 77.5] at index visits were included, with follow-up imaging taken at an average interval of 6.2 [6.0, 8.3] months. For the whole cohort, maximum <math> <mover><msub><mi>ε</mi> <mrow><mi>ρ</mi> <mo>+</mo></mrow> </msub> <mo>¯</mo></mover> <mrow><mo>/</mo> <mi>PP</mi></mrow> </math> decreased from 2.1 [1.1, 2.7] %/mmHg to 1.9 [1.3, 2.6] %/mmHg (<i>p</i> = 0.08), and maximum AAA diameter increased from a median of 4.3 [4.0, 4.7] cm to 4.4 [4.1, 4.9] cm (<i>p</i> = 0.04). The \"high-strain\" tercile was associated with a strain reduction of -1.3 [-2.5, -1.1] %/mmHg between index and follow-up imaging, as compared to the \"low-strain\" (-0.1 [-0.6, 0.5] %/mmHg, <i>p</i> < 0.01) and \"intermediate-strain\" (-0.4 [-0.5, -0.3] %/mmHg, <i>p</i> = 0.04) terciles. There was no difference in the rate of AAA growth, intervention, or rupture between terciles.</p><p><strong>Discussion: </strong>The present findings indicate that <math> <mover><msub><mi>ε</mi> <mrow><mi>ρ</mi> <mo>+</mo></mrow> </msub> <mo>¯</mo></mover> <mrow><mo>/</mo> <mi>PP</mi></mrow> </math> at baseline predicts the degree and direction of <math> <mover><msub><mi>ε</mi> <mrow><mi>ρ</mi> <mo>+</mo></mrow> </msub> <mo>¯</mo></mover> <mrow><mo>/</mo> <mi>PP</mi></mrow> </math> change in AAAs over time. These findings offer insight into the natural history of AAA tissue mechanics and demonstrate the potential for a novel ultrasound technique to quantify biomechanical changes in the aortic wall. These findings may aid in the development of patient-specific risk stratification tools informed by biomechanical data in addition to conventional size-based criteria.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1613881"},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Mushroom in the heart\": a <i>Volvariella volvacea</i> infective endocarditis case report.","authors":"Yunhan Mao, XinPei Liu, ChaoJi Zhang, Jun Zheng","doi":"10.3389/fcvm.2025.1643975","DOIUrl":"10.3389/fcvm.2025.1643975","url":null,"abstract":"<p><p><i>Volvariella volvacea (V. volvacea)</i>, an edible mushroom, may act as a pathogenic agent causing invasive fungal infections (IFIs) in immunocompromised patients. We present a 38-year-old male with persistent high fever post-allo-HSCT. Plasma mNGS revealed rising <i>V. volvacea</i> DNA loads (1,137 copies/μl). Intravenous antifungal therapy was initiated upon the diagnosis of IFI. Transthoracic echocardiography showed a 4 × 1 cm left atrial vegetation, with enhanced CT confirming multiorgan septic emboli (brain and kidney). PET/CT revealed a left atrial vegetation originating from a right lung infectious lesion, spreading contiguously into the left atrium via the pulmonary vein. Urgent vegetation resection was performed, followed by continued intravenous antifungal treatment. At the 5-month follow-up, the patient was afebrile with negative mNGS, completely resolved pulmonary lesion, and an improved quality of life. This case highlights the potential value of surgical-targeted antifungal therapy for fungal endocarditis and suggests practical principles: including mNGS-guided diagnosis, urgent surgical excision, long-term optimized antifungal therapy, and regular follow-up surveillance of the residual infected lesion.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1643975"},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Application of the AngioJet thrombectomy system in acute lower extremity deep vein thrombosis complicated by transplanted renal vein thrombosis (report of two cases).","authors":"Lifan Shao, Guangxin Cao, Suiyuan Shang, Bo Sun, Wuguang Ji, Jiefeng Zhang, Tao Liu","doi":"10.3389/fcvm.2025.1513776","DOIUrl":"10.3389/fcvm.2025.1513776","url":null,"abstract":"<p><p>Lower extremity deep venous thrombosis (DVT) combined with transplanted renal vein thrombosis represents a rare and complex form of venous thromboembolism that leads to obstruction of the transplanted renal vein. This condition results in parenchymal edema of the kidney, ultimately impairing the function of the transplanted organ. It constitutes a catastrophic complication following renal transplantation, potentially resulting in loss of function of the transplanted kidney and failure of the surgical procedure. The primary objective of treatment is to promptly remove thrombi from the transplanted renal vein, thereby restoring normal venous return and renal function as swiftly as possible to enhance patient prognosis. Currently, surgical thrombectomy and thrombolytic therapy are considered the mainstay treatment modalities. Surgical thrombectomy is generally recommended as a first-line approach due to its efficacy in achieving rapid thrombus removal. To date, there exists limited literature regarding the utilization of the AngioJet thrombectomy system for managing DVT in conjunction with transplanted renal vein thrombosis. In this report, we present two cases involving middle-aged male patients diagnosed with acute lower extremity DVT complicated by transplanted renal vein thrombosis. Both patients had undergone allogeneic kidney transplantation 15 and 4 years prior, respectively. In these instances, we employed the AngioJet thrombectomy system for emergency thrombus aspiration treatment. The thrombi within both patients' lower extremity deep veins and their respective transplanted renal veins were completely removed. Subsequently, urine output gradually increased for both patients; moreover, their renal function progressively improved to an acceptable range. Notably, neither patient developed postoperative complications nor exhibited any recurrence of thrombi during follow-up evaluations.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1513776"},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Composition of cardiac-derived extracellular vesicles changes with vesicle origin and determines uptake.","authors":"Sruti Bheri, Jessica R Hoffman, Hyun-Ji Park, Swarnima Roychowdhury, Felipe Takaesu, Samuel G Moore, David A Gaul, Michael E Davis","doi":"10.3389/fcvm.2025.1565104","DOIUrl":"10.3389/fcvm.2025.1565104","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular disease (CVD) is a leading cause of mortality worldwide. The potency of cell-based therapies for CVD is increasingly attributed to the release of small extracellular vesicles (sEVs) which consist of a lipid/protein membrane and encapsulate nucleic cargo. Specifically, sEVs from ckit + progenitor cells (CPCs) and mesenchymal stromal cells (MSCs) are shown to be pro-reparative, with clinical trials conducted. Despite copious research into sEV cargo, the role of parent cell type on sEV membrane composition and its effects on sEV uptake mechanism by recipient cells remain unclear. This is crucial for designing sEV-based therapeutics as uptake mechanism dictates the functionality of the cargo.</p><p><strong>Methods: </strong>In this study we investigate the role of sEV parent cell and membrane composition on the mechanism of EV uptake by recipient cells.</p><p><strong>Results: </strong>We find that sEV membrane lipid and protein composition varies by parent cell type. Further, vesicle uptake mechanism varies by both sEV parent cell type and recipient cell type, with clathrin-mediated uptake being the most variable across parent cell conditions. Using a partial least squares regression model, we observe that proteins important in clathrin-mediated uptake (e.g., TPM1, MRC2, FSTL1, LTBP1) are dissimilar to other vesicle uptake mechanisms.</p><p><strong>Discussion: </strong>This work underscores the importance of the sEV source and membrane composition on uptake, and in turn the importance of selecting specific sEVs based on the target recipient cells for CVD therapies.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1565104"},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Obesity, metabolic abnormalities and low-grade inflammation: differencial associations with subclinical atherosclerosis\".","authors":"Sergio González, Máximo Schiavone, Federico Piñero, Renzo Melchiori, Noelia Brenzoni, Guido García, Pamela Alarcón, Fabián Ferroni, Sergio Baratta, Carlos Castellaro","doi":"10.3389/fcvm.2025.1607399","DOIUrl":"10.3389/fcvm.2025.1607399","url":null,"abstract":"<p><strong>Background & aims: </strong>Obesity is associated with an increased risk of atherosclerosis, though recent evidence shows conflicting results. This study aimed to evaluate whether obesity or its association with metabolic abnormalities (MAs) and low-grade inflammation play a more significant role in atherosclerosis development in a primary care population.</p><p><strong>Methods: </strong>A cross-sectional study using data from the Cardiometabolic Risk Factor Registry (CARFARE) at Hospital Universitario Austral included adults undergoing their first healthcare visit for primary cardiovascular prevention. Participants were classified into four groups: metabolically healthy non-obese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy non-obese (MUNO), and metabolically unhealthy obese (MUO), according to the BioShare-EU criteria and body mass index. MAs were defined by the same criteria. Inflammation was estimated through absolute Neutrophil (NEU) count. Atherosclerosis prevalence was analyzed using univariate analysis and multivariable logistic regression models.</p><p><strong>Results: </strong>Among 6,735 participants, 23.3% were MHNO, 3.13% MHO, 45.6% MUNO, and 27.9% MUO. MHO subjects were 10.1% of the obese population. In univariate analysis, atherosclerosis prevalence was higher in obese than non-obese individuals (57.1% vs. 52.0%, <i>p</i> = 0.001), but lower in MHNO and MHO compared to MUNO and MUO groups (33.1% and 34.4% vs. 60.4% and 59.5%, <i>p</i> < 0.0001). In multivariate regressions, these latter groups presented an increased adjusted odds ratio (aOR) of atherosclerosis compared to MHNO, while atherosclerosis prevalence was no different between the MHO and MHNO groups [aOR: 0.77 (95% CI: 0.54-1.10)]. Moreover, in a second logistic regression model, MAs [aOR: 1.82 (95% CI: 1.58-2.10)] and NEU were independently associated with atherosclerosis [aOR: 1.08 (95% CI: 1.03-1.14)], while obesity was not [aOR: 0.88 (95% CI: 0.77-1.01)].</p><p><strong>Conclusion: </strong>In this primary care population, the MHO phenotype was not associated with increased atherosclerosis. MAs and inflammation, rather than obesity alone, were independently associated with atherosclerosis. These findings highlight the need for further longitudinal studies to clarify the interactions between obesity and metabolic health in atherosclerosis development.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1607399"},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L-shaped association of low-density lipoprotein cholesterol with all-cause and cardiovascular mortality in cancer survivors: a population-based cohort study.","authors":"Bowen Hou, Yali Hu, Hairong Wang, Huang Zhang, Xingyu Gao, Ying Cui, Yilin Zhao, Jing Xie, Xiaomei Yu, Lang Wang, Hong Jiang, Lihua Zhu","doi":"10.3389/fcvm.2025.1593824","DOIUrl":"10.3389/fcvm.2025.1593824","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the association between LDL-C levels and all-cause, cardiovascular, and cancer mortality in cancer survivors, and to identify the LDL-C level associated with the lowest mortality risk, using data from NHANES 1999-2018.</p><p><strong>Study design: </strong>Population-based cohort study.</p><p><strong>Methods: </strong>We analyzed 1,958 U.S. cancer survivors from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. We used Cox and Fine-Gray model to compare mortality risks across LDL-C quartiles, combined with restricted cubic spline analysis to assess nonlinear relationships, and piecewise linear regression to identify LDL-C inflection points.</p><p><strong>Results: </strong>During a median follow-up of 7.3 years (681 deaths were recorded), we observed a nonlinear association between LDL-C levels and all-cause/cardiovascular mortality, wherein low levels of LDL-C were associated with an increased mortality risk. The identified optimal LDL-C thresholds were 119 mg/dl for all-cause mortality and 124 mg/dl for cardiovascular mortality. Age and CVD history influenced the association, with a negative linear relationship between LDL-C and all-cause mortality observed in individuals aged under 65 years and those in the primary CVD prevention.</p><p><strong>Conclusions: </strong>Cancer survivors with low LDL-C levels were correlated with elevated all-cause and CVD mortality risks, particularly in younger patients and those without prior CVD.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1593824"},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of SGLT2i administration in dilated cardiomyopathy: protocol for a systematic review and meta-analysis.","authors":"Ruolan Hu, Li Yu, Jinrong Li, Lei Liu, Yifei Li","doi":"10.3389/fcvm.2025.1575493","DOIUrl":"10.3389/fcvm.2025.1575493","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a promising treatment for heart failure and cardiomyopathy. Furthermore, recent research has explored the use of SGLT2i in patients with dilated cardiomyopathy (DCM). However, the evidence that SGLT2i can improve left ventricular function and reduce symptoms of heart failure in DCM patients is limited.</p><p><strong>Objective: </strong>The objective of our study was to assess the efficacy and safety of SGLT2i in managing DCM patients with heart failure and to predict its effectiveness in DCM patients without heart failure. The benefits of SGLT2i alone or in combination will also be determined.</p><p><strong>Methods: </strong>A structured search of bibliographic databases (PubMed, Embase, and the Cochrane Central Register of Controlled Trials) will be undertaken to retrieve randomized controlled trials and cohorts that describe the efficacy and safety of SGLT2i as a major therapy strategy for DCM patients. To ensure that all relevant data were captured, the search did not contain any restrictions on language or publication time. Primary efficacy outcomes will be all-causes mortality and cardiovascular mortality. Primary safety outcomes will be the incidence of hypoglycemia, liver and renal injuries, and recurrent respiratory tract infections. After deduplication, citations will be screened independently by 2 authors, and selected for inclusion based on prespecified criteria. Data extraction and risk of bias assessment will be performed independently and in duplicate.</p><p><strong>Conclusions: </strong>This study could potentially provide new insights into the therapeutic strategies for dilated cardiomyopathy patients and reforming clinical guidelines for using SGLT2i to ensure patient safety and medicine efficacy.</p><p><strong>Trial registration: </strong>PROSPERO CRD42023417892.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1575493"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2i use is associated with reduced risks of cardiopulmonary inflammatory complications in cancer patients with diabetes: a retrospective cohort study.","authors":"Dan Li, Yanlin Li, Lingyu Meng, Xin Yu, Min Jiao","doi":"10.3389/fcvm.2025.1657240","DOIUrl":"10.3389/fcvm.2025.1657240","url":null,"abstract":"<p><strong>Background: </strong>Chronic low-grade inflammation constitutes a shared pathological mechanism linking type 2 diabetes mellitus (T2DM) and malignancies. While preclinical evidence suggests SGLT2 inhibitors (SGLT2i) may attenuate chronic inflammation, clinical data regarding their protective effects against multi-system inflammatory complications during anti-tumor therapy remain scarce.</p><p><strong>Objective: </strong>This study examined the association between SGLT2i use and the risk of cardiopulmonary inflammatory complications following anti-tumor therapy in cancer patients with diabetes.</p><p><strong>Methods: </strong>We conducted a retrospective, propensity score-matched cohort study at the First Affiliated Hospital of Xi'an Jiaotong University. Patients diagnosed with T2DM and cancer between March 2017 and March 2024, who survived over one year after initiating anti-tumor therapy, were included. Participants were stratified into SGLT2i users and non-users based on pre-treatment exposure. Non-SGLT2i users were matched 1:1 to users by age, sex, cancer stage, hemoglobin A1c (HbA1c), and estimated glomerular filtration rate (eGFR) levels. The primary outcome was a composite of cardiopulmonary inflammatory complications (pneumonia, pleural effusion, and pericardial effusion).</p><p><strong>Results: </strong>Among 1,183 eligible patients with T2DM and cancer, 103 received SGLT2i before anti-tumor therapy (SGLT2i group) and were matched with 103 non-SGLT2i users. Over the median follow-up period of 48 months, the SGLT2i group had a significantly lower risk of composite events (15.53% vs. 35.92%, <i>p</i> = 0.002) than the non-SGLT2i group, with reduced risks for pneumonia (9.71% vs. 22.33%, <i>p</i> = 0.030), pleural effusion (5.83% vs. 17.48%, <i>p</i> = 0.025), and pericardial effusion (2.91% vs. 10.68%, <i>p</i> = 0.030).</p><p><strong>Conclusion: </strong>In cancer patients with diabetes, pre-treatment SGLT2i use is associated with reduced risks of cardiorespiratory inflammatory complications. Robust prospective studies are warranted to confirm the role of SGLT2i in mitigating multi-system inflammatory risks in this cohort.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1657240"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}